Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
12
|
pubmed:dateCreated |
1996-1-22
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0002-953X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
152
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1833
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:8526260-Antipsychotic Agents,
pubmed-meshheading:8526260-Drug Administration Schedule,
pubmed-meshheading:8526260-Humans,
pubmed-meshheading:8526260-Parkinson Disease,
pubmed-meshheading:8526260-Psychotic Disorders,
pubmed-meshheading:8526260-Recurrence,
pubmed-meshheading:8526260-Risperidone,
pubmed-meshheading:8526260-Treatment Outcome
|
pubmed:year |
1995
|
pubmed:articleTitle |
"Awakenings" effect with risperidone.
|
pubmed:publicationType |
Letter
|